1.
Kalev D.,
Yonkov A.,
Stoyanova A.,
Balev B.,
et al., Bulgarian Guidelines for Neuroblastoma in Children (Bulgarian language publication),
Varna,
2015,
ISBN 978-619-7094-15-2
2.
Radiopaedia.org
3.
ACCIS: Automated Childhood Cancer Information System,
http://acciss.iarc.fr
4.
Adam A.,
Dixon A.,
Grainger and Allison’s Diagnostic Radiology - A Textbook of Medical Imaging,
5th Edition,
Churchill Livingstone,
An Imprint of Elsevier,
2008
5.
Brant W.,
Helms C.,
Fundamentals of Diagnostic Radiology,
3rd Edition,
Lippincott Williams & Wilkins,
2007
6.
The Gentle Way - The Art of Pediatric Imaging,
ESR,
2015
7.
Gunderman R.,
Essential Radiology,
Thieme,
2006
8.
Wells R.,
Diagnostic Imaging of Infants and Children,
McGraw-Hill,
2013,
ISBN: 978-0-07-180839-2
9.
Donnelly,
Merrow,
Anton,
O'Hara,
Jones,
Diagnostic Imaging Pediatrics,
Second Edition,
ISBN-10: 1931884846
10.
Papaioannou G.,
McHugh K.,
Neuroblastoma in childhood: review and radiological findings,
Cancer Imaging,
2005,
5(1): 116-127,
doi: https://dx.doi.org/10.1102%2F1470-7330.2005.0104
11.
Brodeur G.,
Maris JM.,
Neuroblastoma,
In: Principles and Practice of Pediatric Oncology,
Ed.
By Pizzo P.
and Poplack D.G.
Lippincott Williams & Wilkins,
5th ed.,(2006): 933-970
12.
Ries L.,
Smith M.,
Gurney J.,
et al,
Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995,
Bethesda,
MD: National Cancer Institute; 1999
13.
Kerbl R,
et al.
Neuroblastoma screening in infants postponed after the sixth month of age: A trial to reduce “Overdiagnosis” and to detect cases with “Unfavorable” biologic features.
Med Pediatr Oncol 1997; 29: 1-10
14.
Parker L,
et al.
Screening for neuroblastoma in infants younger than 1 year of age: Review of the first 30 years.
Med Pediatr Oncol 1998; 31: 455-469
15.
Kerbl R,
et al.
Treatment complications in neuroblastoma patients: Lessons from screening studies.J Clin Oncol 2006; 24: e41
16.
Ladenstein R,
at al.
What can we expect from neuroblastoma screening? Clinicians point of view.
Med Pediatr Oncol 1998; 31: 408-418
17.
Hugosson C,
R.
Nyman,
H.
Jorulf,
P.
McDonald,
A.
Rifai,
A.
Kofide,
B.
Jacobsson.
Imaging of Abdominal Neuroblastoma in Children.
Acta Radiol 1999; 40 (5): 534-542
18.
LNESG2-STUDY final draft June 1st 2004; amendment # 1,
December 1,
2006
19.
Brodeur G.,
Pritchard J.,
Berthold F.
et-al.
Revisions of the international criteria for neuroblastoma diagnosis,
staging,
and response to treatment.
J.
Clin.
Oncol.
1993;11 (8): 1466-77.
20.
Monclair T.,
Brodeur G.,
Ambros P.,
Brisse H.,
Cecchetto G.
Holmes K.,
Kaneko M.,
London WB.
Matthay K.,
Nuchtern J.,
von Schweinitz D.,
Cohn S.,
and Pearson A.,
INRG Task Force.
The International Neuroblastoma Risk Group (INRG) Staging System.
J.
Clin.
Oncol.,
27:298-303,
2009,
http://inrgdb.org/neuroblastoma-information/staging-system/
21.
Brisse,
McCarville,
Granata,
et al.
Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project,
Radiology,
v.261,
1,
2011
22.
Owens C.,
Gillard J.,
Grainger and Allison's Diagnostic Radiology: Paediatric Imaging,
Elsevier Health Sciences,
24.11.2015
23.
Chu C.,
Rasalkar D.,
Hu Y.,
et al.
Clinical presentations and imaging findings of neuroblastoma beyond abdominal mass and a review of imaging algorithm.
Br J Radiol 2011; 84 (997): 81-91
24.
Lumbroso J.,
et al.Sensitivity and specificity of meta-iodobenzylguanidine (mIBG) scintigraphy in the evaluation of neuroblastoma: analysis of 115 cases.
Bull Cancer 1988; 75 (1): 97-106
25.
Vik T.,
et al.
(123)I-mIBGscintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial.
Pediatr Blood Cancer 2009; 52: 784-790
26.
Matthay K.,
et al.
Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.
Br J Cancer 2010; 102 (9): 1319-1326
27.
Piccardo A.,
et al.
Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.
Eur J Nucl Med Mol Imaging 2012; 39 (1): 57-71
28.
Piccardo A.,
et al.
Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma.
Eur J Nucl Med Mol Imag 2014; 41 (6): 1046-1056
29.
Lenhard R.,
Osteen R.,
Gansler T.,
et-al.
Clinical oncology.
Wiley-Blackwell.
(2001) ISBN:0944235158.
30.
Kumar V.,
Abbas A.,
Fausto N.,
et-al.
Robbins and Cotran pathologic basis of disease.
W B Saunders Co.
(2005) ISBN:0721601871.
31.
Oberthuer A.,
Theissen J.,
Westermann F.,
Hero B.,
Fischer M.,Molecular Characterization and Classification of Neuroblastoma,
Future Oncol.
2009;5(5):625-639.
32.
German Neuroblastoma Trial NB2004,
results at: http://www.kinderkrebsinfo.de/sites/kinderkrebsinfo/content/e1676/e9032/e1758/e7671/download7673/NB_2004_1.00_komprimiert__ger.pdf